Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2022 19:50 ET | Source: Mesoblast Limited

Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
October 02, 2022 19:52 ET | Source: Mesoblast Limited

Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

NEW YORK, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that it has submitted...
August 30, 2022 19:05 ET | Source: Mesoblast Limited

Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022

At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gross proceeds of US$45 million via a private placement in August, 2022 Up to an additional US$40...
August 29, 2022 20:14 ET | Source: Mesoblast Limited

Mesoblast Corporate Update and Financial Results Webcast

NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
August 18, 2022 07:00 ET | Source: Mesoblast Limited

Jane Bell Joins Mesoblast Board

NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed...
July 29, 2022 07:05 ET | Source: Mesoblast Limited

Appendix 4C Quarterly Activity Report

NEW YORK, July 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
July 11, 2022 20:40 ET | Source: Mesoblast Limited

Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management

NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L,...
June 09, 2022 07:00 ET | Source: Mesoblast Limited

Mesoblast Key Opinion Leader Event Series for Investors & Analysts

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the...
May 31, 2022 20:15 ET | Source: Mesoblast Limited

Operational Highlights and Financial Results for the Period Ended March 31, 2022

NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...
April 28, 2022 20:35 ET | Source: Mesoblast Limited

Appendix 4C Quarterly Activity Report

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right